These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
2026 mein: effervescent format (not capsule), 500mg dose, ALA + NAC co-factors, FSSAI number on label, GMP manufacturing, aur Japanese-fermented glutathione source
The process is still individualized though - each person gets their own medical consultation and can choose their preferred cocktail based on their health needs and goals
[PMC free article] [PubMed] [Google Scholar] 191.Chang JC, Hsu SH, Chen DC
Its stability in human gastric juice and potential oral bioactivity make it a rare peptide with possible systemic benefits even when taken non-injectably
